|
Re: Abstract - first example of a "curative" effect?
|
3
|
Resverlogix Corp.
|
Oct 11, 2018 05:42AM
|
|
Arvinas /ARVN dBET vs iBET
|
4
|
Zenith Epigenetics
|
Oct 12, 2018 08:03PM
|
|
Re: Arvinas /ARVN dBET vs iBET
|
2
|
Zenith Epigenetics
|
Oct 13, 2018 04:05PM
|
|
Re: HDL function is associated with atherosclerotic burden and cardiovascular outcomes in T2D
|
3
|
Resverlogix Corp.
|
Oct 16, 2018 05:07PM
|
|
Re: HDL function is associated with atherosclerotic burden and cardiovascular outcomes in T2D
|
1
|
Resverlogix Corp.
|
Oct 16, 2018 06:57PM
|
|
Re: Resverlogix October 2018 events
|
2
|
Resverlogix Corp.
|
Oct 17, 2018 11:33PM
|
|
Re: Resverlogix October 2018 events
|
3
|
Resverlogix Corp.
|
Oct 18, 2018 09:17AM
|
|
Endocyte Valuation
|
4
|
Zenith Epigenetics
|
Oct 18, 2018 02:14PM
|
|
Re: Roth research report
|
4
|
Resverlogix Corp.
|
Nov 01, 2018 09:14AM
|
|
Re: Roth research report
|
|
Resverlogix Corp.
|
Nov 01, 2018 09:20AM
|
|
Re: RVX closes PP...getting US money in?
|
6
|
Resverlogix Corp.
|
Nov 02, 2018 04:34PM
|
|
Re: 3 point MACE vs 5 point MACE
|
2
|
Resverlogix Corp.
|
Nov 02, 2018 06:27PM
|
|
Re: 3 point MACE vs 5 point MACE
|
1
|
Resverlogix Corp.
|
Nov 02, 2018 06:39PM
|
|
Re: 3 point MACE vs 5 point MACE
|
2
|
Resverlogix Corp.
|
Nov 02, 2018 11:06PM
|
|
Re: 3 point MACE vs 5 point MACE
|
5
|
Resverlogix Corp.
|
Nov 03, 2018 04:38AM
|
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 03, 2018 01:02PM
|
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 04, 2018 06:16AM
|
|
Re: MACE event rate
|
4
|
Resverlogix Corp.
|
Nov 04, 2018 08:24AM
|
|
Re: MACE event rate
|
4
|
Resverlogix Corp.
|
Nov 04, 2018 10:58AM
|
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 04, 2018 11:16AM
|
